List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2776291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study. Diseases of the Colon and Rectum, 2023, 66, e996-e1005.	1.3	8
2	A nomogram for predicting cancer specific survival (CSS) in patients with pathological T3N0M0 (pT3N0M0) rectal cancer Journal of Clinical Oncology, 2022, 40, 113-113.	1.6	0
3	SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer Journal of Clinical Oncology, 2022, 40, 117-117.	1.6	1
4	Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Research, 2022, 32, 530-542.	12.0	54
5	B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. Journal of Immunotherapy, 2022, 45, 187-193.	2.4	14
6	Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. Nature Communications, 2022, 13, 2342.	12.8	21
7	High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer. Radiation Oncology, 2022, 17, 98.	2.7	1
8	Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning. EBioMedicine, 2022, 81, 104120.	6.1	9
9	Colorectal cancer under 20Âyears old: a retrospective analysis from three tertiary hospitals. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1145-1155.	2.5	6
10	Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cancer Letters, 2021, 500, 119-131.	7.2	8
11	Development and external validation of a novel nomogram for screening Chinese Lynch syndrome: based on a multicenter, population study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110232.	3.2	3
12	The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers. Experimental Hematology and Oncology, 2021, 10, 2.	5.0	14
13	Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. Journal of Medical Genetics, 2021, , jmedgenet-2020-107230.	3.2	11
14	Primary tumor immune score fails to predict the prognosis of colorectal cancer liver metastases after hepatectomy in Chinese populations. Annals of Translational Medicine, 2021, 9, 310-310.	1.7	5
15	Predicting treatment response from longitudinal images using multi-task deep learning. Nature Communications, 2021, 12, 1851.	12.8	87
16	Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. , 2021, 9, e001498.		28
17	Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome. Radiation Oncology, 2021, 16, 93.	2.7	2
18	Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology, 2021, 14, 80.	17.0	90

#	Article	IF	CITATIONS
19	Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Science, 2021, 112, 3607-3615.	3.9	3
20	Clinical characteristics and prognostic factors of colorectal cancer patients with ovarian metastasis: a multicenter retrospective study. International Journal of Colorectal Disease, 2021, 36, 1201-1208.	2.2	2
21	The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy. Radiation Oncology, 2021, 16, 16.	2.7	32
22	A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study. BMC Medicine, 2021, 19, 250.	5.5	5
23	Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment. International Journal of Pharmaceutics, 2020, 573, 118637.	5.2	40
24	Phase III randomized, placeboâ€controlled, doubleâ€blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatinâ€induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer Medicine, 2020, 9, 151-159.	2.8	18
25	Low prevalence of mismatch repair deficiency in Chinese colorectal cancers: a multicenter study. Gastroenterology Report, 2020, 8, 399-403.	1.3	3
26	Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer. European Journal of Human Genetics, 2020, 28, 1555-1562.	2.8	5
27	Serum piRNA-54265 is a New Biomarker for early detection and clinical surveillance of Human Colorectal Cancer. Theranostics, 2020, 10, 8468-8478.	10.0	58
28	Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Cancer Communications, 2020, 40, 620-632.	9.2	7
29	Serum Gamma Glutamyl transferase is a predictor of recurrence after R0 hepatectomy for patients with colorectal cancer liver metastases. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094797.	3.2	4
30	Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. World Journal of Surgical Oncology, 2020, 18, 98.	1.9	2
31	Signet ring cell component in pretreatment biopsy predicts pathological response to preoperative chemoradiotherapy in rectal cancer. International Journal of Clinical Oncology, 2020, 25, 1653-1662.	2.2	1
32	Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy. Cancer Immunology, Immunotherapy, 2020, 69, 2623-2634.	4.2	21
33	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncolmmunology, 2020, 9, 1711650.	4.6	37
34	Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer Journal of Clinical Oncology, 2020, 38, 4079-4079.	1.6	1
35	Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting. Journal of Cancer, 2019, 10, 388-396.	2.5	4
36	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. JAMA Network Open, 2019, 2, e193433.	5.9	8

#	Article	IF	CITATIONS
37	A frameshift mutation in exon 19 of MLH1 in a Chinese Lynch syndrome family: a pedigree study. Journal of Zhejiang University: Science B, 2019, 20, 105-108.	2.8	5
38	Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study. BMC Cancer, 2019, 19, 1210.	2.6	9
39	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. International Journal of Cancer, 2019, 144, 2161-2168.	5.1	34
40	An early report of a screening program for colorectal cancer in Guangzhou, China. Annals of Translational Medicine, 2019, 7, 604-604.	1.7	8
41	Prolonged surveillance of colorectal cancer patients after curative surgeries beyond five years of follow-up. Annals of Translational Medicine, 2019, 7, 608-608.	1.7	7
42	The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. Journal of the National Cancer Institute, 2018, 110, 975-984.	6.3	32
43	Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a longâ€term analysis of a prospective, singleâ€center, randomized trial. Cancer Communications, 2018, 38, 1-10.	9.2	9
44	Liver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center. Cancer Management and Research, 2018, Volume 10, 6121-6127.	1.9	5
45	The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncolmmunology, 2018, 7, e1488566.	4.6	13
46	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics, 2018, 8, 5213-5230.	10.0	115
47	Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer. Journal of Cancer, 2018, 9, 1365-1370.	2.5	13
48	Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a singleâ€institute phase II study. Cancer Communications, 2018, 38, 1-9.	9.2	25
49	The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunology, Immunotherapy, 2018, 67, 435-444.	4.2	61
50	Effect of increasing radiation dose for rectal cancer patients with nonoperative management after neoadjuvant chemoradiotherapy Journal of Clinical Oncology, 2018, 36, e15676-e15676.	1.6	1
51	The total number of lymph nodes harvested from pathological T3N0 rectal cancer patients: Prognostic significance and potential indication for postoperative radiotherapy. Journal of Cancer Research and Therapeutics, 2018, 14, 288.	0.9	6
52	Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1461-1467.	2.5	22
53	Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC). Journal of Cancer Research and Clinical Oncology, 2017, 143, 2581-2593.	2.5	10
54	Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. Tumor Biology, 2017, 39, 101042831770963.	1.8	15

#	Article	IF	CITATIONS
55	Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. Chinese Journal of Cancer, 2017, 36, 78.	4.9	11
56	Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study. Oncology Letters, 2017, 14, 4543-4550.	1.8	6
57	The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?. Journal of Cancer, 2017, 8, 1179-1186.	2.5	17
58	Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis. Aging, 2017, 9, 2334-2351.	3.1	10
59	The correlation between mismatch repair status and clinicopathological characteristics in Chinese colorectal cancer patients Journal of Clinical Oncology, 2017, 35, 544-544.	1.6	1
60	Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: A randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC) Journal of Clinical Oncology, 2017, 35, e15002-e15002.	1.6	0
61	Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis. Gastroenterology Research and Practice, 2016, 2016, 1-10.	1.5	13
62	Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2551-2560.	2.5	35
63	Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chinese Journal of Cancer, 2016, 35, 65.	4.9	22
64	Preoperative chemoradiotherapy creates an opportunity to perform sphincter preserving resection for low-lying locally advanced rectal cancer based on an oncologic outcome study. Oncotarget, 2016, 7, 57317-57326.	1.8	5
65	Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Oncotarget, 2016, 7, 6335-6344.	1.8	22
66	Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer. Clinics, 2016, 71, 449-454.	1.5	13
67	The safety of four cycles of CAPEOX combined with radiotherapy vs. capecitabine combine with radiotherapy for locally advanced rectal cancer: Mid-term analysis of NCT02031939 Journal of Clinical Oncology, 2016, 34, e14040-e14040.	1.6	0
68	Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial. Chinese Journal of Cancer, 2015, 34, 394-403.	4.9	16
69	A Low Lymphocyte-to-Monocyte Ratio Predicts Unfavorable Prognosis in Pathological T3N0 Rectal Cancer Patients Following Total Mesorectal Excision. Journal of Cancer, 2015, 6, 616-622.	2.5	36
70	Identification of Locally Advanced Rectal Cancer with Low Risk of Local Recurrence. PLoS ONE, 2015, 10, e0117141.	2.5	9
71	Multi-center, randomized, controlled, open-label effectiveness study of primary tumor resection or not in asymptomatic colorectal cancer with unresectable metastatic disease Journal of Clinical Oncology, 2015, 33, TPS3628-TPS3628.	1.6	0
72	Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: A Prospective Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1153-1160.	0.8	52

#	Article	IF	CITATIONS
73	Preoperative radiotherapy combined with simultaneous chemotherapy with capecitabine plus oxaliplatin versus surgery alone: A single-centered, phase II study in patients with mid/low rectal cancer Journal of Clinical Oncology, 2014, 32, 609-609.	1.6	1
74	Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: A meta analysis. European Journal of Cancer, 2013, 49, 843-851.	2.8	57
75	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. Annals of Surgery, 2012, 256, 111-116.	4.2	63
76	Depth of Tumor Invasion Independently Predicts Lymph Node Metastasis in T2 Rectal Cancer. Journal of Gastrointestinal Surgery, 2011, 15, 130-136.	1.7	13